tiprankstipranks
TipRanksTop Financial ExpertsInsidersPaul Berns

Paul Berns Insider Profile

4 Followers
Paul Berns, Executive Chair of the Board, Director at Neumora Therapeutics, Inc., holds 15.06M shares in Kardigan, Inc. (Ticker: KARD), holds 7.79M shares in Neumora Therapeutics, Inc. (Ticker: NMRA), holds 0.00 shares in Metsera, Inc. (Ticker: MTSR). Most recently, Paul Berns Bought ― shares of Kardigan, Inc. on Jun 24, 2026 for an estimated value of $20.00M.
See the Hottest Stocks Based on Insider Trading >
tipranks
Paul Berns

Paul Berns
Neumora Therapeutics, Inc. (NMRA)
Executive Chair of the Board, Director

Ranked #28,337 out of 108,921 Corporate Insiders

Profitable Transactions

45%
5 out of 11 Profitable Transactions

Average Return

+4.40%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
How are Insiders Ranked?

Insider Holdings

$326M
96.24%
3.13%
0.63%
0.00%
0.00% Others
A breakdown of Paul Berns's holdings
See the Top Stocks by Insiders

Insider Roles

Kardigan, Inc.
(KARD)
Director, Ten Percent Owner
Neumora Therapeutics, Inc.
(NMRA)
Executive Chair of the Board, Director
Jazz Pharmaceuticals
(JAZZ)
Director
Yarrow Bioscience
(YARW)
Director
+1 other positions
Roles that Paul Berns holds in companies
See the Top Corporate Insiders

Most Profitable Insider Trade

Stock:
Neumora Therapeutics, Inc.
(NMRA)
Rating:Informative Sell
Date:Feb 19, 2026 - Today
Return:+62.30%
The most profitable trade made by Paul Berns
See the Latest Stocks Traded by Insiders

Paul Berns's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
NMRA
Neumora Therapeutics, Inc.
Feb 19, 2026
Executive Chair of the Board, Director
Informative Sell
34.37K
$10.21M
MTSR
Metsera, Inc.
Nov 13, 2025
―
Uninformative Sell
―
$0.00
KARD
Kardigan, Inc.
Jun 24, 2026
Director, Ten Percent Owner
Informative Buy
20.00M
$314.06M
UNBX
Unity Biotechnology
May 07, 2018
―
Uninformative Buy
―
$182.62
YARW
Yarrow Bioscience
―
Director
―
―
EQRX
EQRx, Inc.
Nov 09, 2023
―
Uninformative Sell
―
$0.00
~ANAC
Anacor Pharmaceuticals
Jun 24, 2016
―
Uninformative Sell
22.96M
$26.53M
JAZZ
Jazz Pharmaceuticals
Aug 09, 2021
Director
Informative Sell
223.30K
$2.05M
XNPT
XenoPort
May 21, 2015
―
Uninformative Buy
―
$70.70K
CLRB
Cellectar Biosciences
Apr 21, 2016
Director
Informative Buy
248.83K
$0.00
List of latest transactions for each holding click on a transaction to see Paul Berns's performance on stock
See All Insider Trading from Today

You May Also Like

Meet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.

Paul Berns insider profile FAQ

What is the percentage of profitable transactions made by Paul Berns?
The percentage of profitable transactions made by Paul Berns is 45%.
    What is the average return per transaction made by Paul Berns?
    The average return per transaction made by Paul Berns is 4.40%.
      What stocks does Paul Berns hold?
      Paul Berns holds: NMRA, MTSR, KARD, UNBX, YARW, EQRX, ~ANAC, JAZZ, XNPT, CLRB stocks.
        What was Paul Berns’s latest transaction?
        Paul Berns latest transaction was an Informative Buy of $20.00M.
          What was Paul Berns's most profitable transaction?
          Paul Berns’s most profitable transaction was an Informative Sell of NMRA stock on February 19, 2026. The return on the trade was 62.30%.
            What is Paul Berns's role in Neumora Therapeutics, Inc.?
            Paul Berns's role in Neumora Therapeutics, Inc. is Executive Chair of the Board, Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.